CRISPR Sickle Cell Cure Has Now Treated 10,000 Patients Worldwide

More than 10,000 patients worldwide have now been treated with the CRISPR-based gene-editing therapy for sickle cell disease, according to figures released at the European Hematology Association's annual meeting. The cumulative milestone, reached five years after the therapy's first approval, confirms the durability of the cure and the absence of clinically meaningful off-target events in long-term follow-up.

Why the Numbers Matter

Sickle cell disease affects more than 20 million people globally, with the highest burden in sub-Saharan Africa, India, and the Caribbean. The CRISPR therapy — which uses ex vivo editing of a patient's own hematopoietic stem cells to reactivate fetal hemoglobin — was the first CRISPR-based cure approved in the United States. Reaching 10,000 treated patients is a milestone for access as much as for the science.

"Ten thousand patients means ten thousand families who no longer plan their lives around pain crises. The data also tells us the cure is durable: we are not seeing loss of editing or return of disease," said Dr. Haydar Frangoul of the Sarah Cannon Research Institute.

What the Long-Term Data Shows

Follow-up data from the original pivotal trials, now out to five years, shows that 98.5% of treated patients remain free of vaso-occlusive crises. No off-target editing events of clinical significance have been identified through whole-genome sequencing of patient samples. The therapy's safety profile continues to compare favorably with allogeneic stem cell transplant.

• Patients treated globally: 10,000+
• Vaso-occlusive crisis-free at 5y: 98.5%
• Off-target events: None of clinical significance
• Median age at treatment: 23 (range 2-65)

The Access Question

The remaining challenge is cost. List prices for the therapy remain above $2M per patient in the U.S., and infrastructure requirements — including apheresis, manufacturing slots, and transplant-grade facilities — limit where it can be delivered. New manufacturing partnerships in Ghana, Nigeria, and India are expected to bring prices down meaningfully in 2027 and beyond, with point-of-care versions entering trials next year.

The sickle cell milestone is also informing pipeline programs for beta-thalassemia, severe combined immunodeficiency, and several inherited metabolic disorders. CRISPR-based cures are no longer a one-off scientific achievement. They are becoming a repeatable therapeutic modality.